Post by Nouryon

Getting pharmaceutical products to market in China depends on one key factor: regulatory approval of every component in the formulation. That’s why we’re proud to share that our CEKOL® sodium carboxymethyl cellulose (CMC-Na), produced in Finland, has received approval as an excipient from China’s National Medical Products Administration (NMPA). It marks an important step forward for our high-quality CMC-Na portfolio in the Chinese pharmaceutical market. Often described as a reliable backbone in formulations, CMC-Na enables essential functions like thickening, stabilization, emulsification, film formation, and controlled release. It is widely used in topical applications, including flurbiprofen and lidocaine gels and ointments. Produced in Finland, CEKOL® CMC-Na is plant-based and trusted by leading global pharmaceutical companies. It offers: - Pharma-grade purity with precisely controlled viscosity and degree of substitution - A strong safety profile and broad formulation compatibility - Robust quality and traceability, backed by pharmacopeial compliance, ISO 9001/14001, and FSSC 22000 Together, these attributes support consistent performance and help meet evolving regulatory expectations for pharmaceutical excipients across global markets. Learn more ➡️ https://ow.ly/Ti4U50Ze7up